Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility

Raffaele Capasso, Gabriella Aviello, Francesca Borrelli, Barbara Romano, Matteo Ferro, Luigi Castaldo, Vittorino Montanaro, Vincenzo Altieri, Angelo A Izzo

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

OBJECTIVES: To evaluate the effect of a Cannabis sativa extract enriched in cannabidiol (CBD) botanic drug substance (BDS) and pure CBD, on bladder contractility in vitro. Cannabis based-medicines, including CBD-enriched extracts, have been shown to reduce urinary urgency, incontinence episodes, frequency, and nocturia in patients with multiple sclerosis.

METHODS: Strips were cut from male Wistar rats and the human bladder body and placed in organ baths containing Krebs solution. Contractions were induced by electrical field stimulation, acetylcholine, KCl, and α,β-methylene adenosine triphosphate.

RESULTS: CBD BDS significantly reduced the contractions induced by acetylcholine, but not those induced with electrical field stimulation, KCl, or α,β-methylene adenosine triphosphate in the isolated rat bladder. The inhibitory effect of CBD BDS was not significantly modified by the cannabinoid or opioid receptor antagonists or by modulators of calcium levels, but it was increased by ruthenium red and capsazepine, 2 transient receptor potential vanilloid type-1 blockers. In humans, CBD BDS and pure CBD significantly reduced acetylcholine-induced contractions, an effect that was not changed by the transient receptor potential vanilloid type-1 blockers.

CONCLUSIONS: Our data have suggested that CBD BDS reduces cholinergic-mediated contractility and that this effect is modulated by transient receptor potential vanilloid type-1 in rats but not in humans. CBD is the chemical ingredient of CBD BDS responsible for such activity. If confirmed in vivo, such results could provide a pharmacologic basis to explain, at least in part, the efficacy of Cannabis medicines in reducing incontinence episodes in patients with multiple sclerosis.

Original languageEnglish
Pages (from-to)1006.e9-1006.e15
Number of pages7
JournalUrology
Volume77
Issue number4
Early online date18 Feb 2011
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Cannabidiol
Cannabis
Urinary Bladder
Pharmaceutical Preparations
Acetylcholine
Electric Stimulation
Multiple Sclerosis
Adenosine Triphosphate
Cannabinoid Receptor Antagonists
Nocturia
Ruthenium Red
Narcotic Antagonists
Urinary Incontinence
Baths
Human Body
Cholinergic Agents
Wistar Rats
Medicine

Keywords

  • Acetylcholine
  • Animals
  • Cannabidiol
  • Cannabis
  • Cholinergic Agonists
  • Humans
  • In Vitro Techniques
  • Male
  • Multiple Sclerosis
  • Muscle Contraction
  • Muscle, Smooth
  • Plant Extracts
  • Rats
  • Rats, Wistar
  • Urinary Bladder
  • Urinary Incontinence
  • Journal Article

Cite this

Capasso, R., Aviello, G., Borrelli, F., Romano, B., Ferro, M., Castaldo, L., ... Izzo, A. A. (2011). Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. Urology, 77(4), 1006.e9-1006.e15. https://doi.org/10.1016/j.urology.2010.12.006

Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. / Capasso, Raffaele; Aviello, Gabriella; Borrelli, Francesca; Romano, Barbara; Ferro, Matteo; Castaldo, Luigi; Montanaro, Vittorino; Altieri, Vincenzo; Izzo, Angelo A.

In: Urology, Vol. 77, No. 4, 04.2011, p. 1006.e9-1006.e15.

Research output: Contribution to journalArticle

Capasso, R, Aviello, G, Borrelli, F, Romano, B, Ferro, M, Castaldo, L, Montanaro, V, Altieri, V & Izzo, AA 2011, 'Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility', Urology, vol. 77, no. 4, pp. 1006.e9-1006.e15. https://doi.org/10.1016/j.urology.2010.12.006
Capasso, Raffaele ; Aviello, Gabriella ; Borrelli, Francesca ; Romano, Barbara ; Ferro, Matteo ; Castaldo, Luigi ; Montanaro, Vittorino ; Altieri, Vincenzo ; Izzo, Angelo A. / Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility. In: Urology. 2011 ; Vol. 77, No. 4. pp. 1006.e9-1006.e15.
@article{fdee926f8e83499c8fdb07b150b5b813,
title = "Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility",
abstract = "OBJECTIVES: To evaluate the effect of a Cannabis sativa extract enriched in cannabidiol (CBD) botanic drug substance (BDS) and pure CBD, on bladder contractility in vitro. Cannabis based-medicines, including CBD-enriched extracts, have been shown to reduce urinary urgency, incontinence episodes, frequency, and nocturia in patients with multiple sclerosis.METHODS: Strips were cut from male Wistar rats and the human bladder body and placed in organ baths containing Krebs solution. Contractions were induced by electrical field stimulation, acetylcholine, KCl, and α,β-methylene adenosine triphosphate.RESULTS: CBD BDS significantly reduced the contractions induced by acetylcholine, but not those induced with electrical field stimulation, KCl, or α,β-methylene adenosine triphosphate in the isolated rat bladder. The inhibitory effect of CBD BDS was not significantly modified by the cannabinoid or opioid receptor antagonists or by modulators of calcium levels, but it was increased by ruthenium red and capsazepine, 2 transient receptor potential vanilloid type-1 blockers. In humans, CBD BDS and pure CBD significantly reduced acetylcholine-induced contractions, an effect that was not changed by the transient receptor potential vanilloid type-1 blockers.CONCLUSIONS: Our data have suggested that CBD BDS reduces cholinergic-mediated contractility and that this effect is modulated by transient receptor potential vanilloid type-1 in rats but not in humans. CBD is the chemical ingredient of CBD BDS responsible for such activity. If confirmed in vivo, such results could provide a pharmacologic basis to explain, at least in part, the efficacy of Cannabis medicines in reducing incontinence episodes in patients with multiple sclerosis.",
keywords = "Acetylcholine, Animals, Cannabidiol, Cannabis, Cholinergic Agonists, Humans, In Vitro Techniques, Male, Multiple Sclerosis, Muscle Contraction, Muscle, Smooth, Plant Extracts, Rats, Rats, Wistar, Urinary Bladder, Urinary Incontinence, Journal Article",
author = "Raffaele Capasso and Gabriella Aviello and Francesca Borrelli and Barbara Romano and Matteo Ferro and Luigi Castaldo and Vittorino Montanaro and Vincenzo Altieri and Izzo, {Angelo A}",
note = "To Enrico and Enrica Sovena Foundation and GW Pharmaceuticals (Porton Down, Wiltshire, UK) for providing us with CBD and CBD BDS.",
year = "2011",
month = "4",
doi = "10.1016/j.urology.2010.12.006",
language = "English",
volume = "77",
pages = "1006.e9--1006.e15",
journal = "Urology",
issn = "0090-4295",
publisher = "Elsevier Inc.",
number = "4",

}

TY - JOUR

T1 - Inhibitory effect of standardized cannabis sativa extract and its ingredient cannabidiol on rat and human bladder contractility

AU - Capasso, Raffaele

AU - Aviello, Gabriella

AU - Borrelli, Francesca

AU - Romano, Barbara

AU - Ferro, Matteo

AU - Castaldo, Luigi

AU - Montanaro, Vittorino

AU - Altieri, Vincenzo

AU - Izzo, Angelo A

N1 - To Enrico and Enrica Sovena Foundation and GW Pharmaceuticals (Porton Down, Wiltshire, UK) for providing us with CBD and CBD BDS.

PY - 2011/4

Y1 - 2011/4

N2 - OBJECTIVES: To evaluate the effect of a Cannabis sativa extract enriched in cannabidiol (CBD) botanic drug substance (BDS) and pure CBD, on bladder contractility in vitro. Cannabis based-medicines, including CBD-enriched extracts, have been shown to reduce urinary urgency, incontinence episodes, frequency, and nocturia in patients with multiple sclerosis.METHODS: Strips were cut from male Wistar rats and the human bladder body and placed in organ baths containing Krebs solution. Contractions were induced by electrical field stimulation, acetylcholine, KCl, and α,β-methylene adenosine triphosphate.RESULTS: CBD BDS significantly reduced the contractions induced by acetylcholine, but not those induced with electrical field stimulation, KCl, or α,β-methylene adenosine triphosphate in the isolated rat bladder. The inhibitory effect of CBD BDS was not significantly modified by the cannabinoid or opioid receptor antagonists or by modulators of calcium levels, but it was increased by ruthenium red and capsazepine, 2 transient receptor potential vanilloid type-1 blockers. In humans, CBD BDS and pure CBD significantly reduced acetylcholine-induced contractions, an effect that was not changed by the transient receptor potential vanilloid type-1 blockers.CONCLUSIONS: Our data have suggested that CBD BDS reduces cholinergic-mediated contractility and that this effect is modulated by transient receptor potential vanilloid type-1 in rats but not in humans. CBD is the chemical ingredient of CBD BDS responsible for such activity. If confirmed in vivo, such results could provide a pharmacologic basis to explain, at least in part, the efficacy of Cannabis medicines in reducing incontinence episodes in patients with multiple sclerosis.

AB - OBJECTIVES: To evaluate the effect of a Cannabis sativa extract enriched in cannabidiol (CBD) botanic drug substance (BDS) and pure CBD, on bladder contractility in vitro. Cannabis based-medicines, including CBD-enriched extracts, have been shown to reduce urinary urgency, incontinence episodes, frequency, and nocturia in patients with multiple sclerosis.METHODS: Strips were cut from male Wistar rats and the human bladder body and placed in organ baths containing Krebs solution. Contractions were induced by electrical field stimulation, acetylcholine, KCl, and α,β-methylene adenosine triphosphate.RESULTS: CBD BDS significantly reduced the contractions induced by acetylcholine, but not those induced with electrical field stimulation, KCl, or α,β-methylene adenosine triphosphate in the isolated rat bladder. The inhibitory effect of CBD BDS was not significantly modified by the cannabinoid or opioid receptor antagonists or by modulators of calcium levels, but it was increased by ruthenium red and capsazepine, 2 transient receptor potential vanilloid type-1 blockers. In humans, CBD BDS and pure CBD significantly reduced acetylcholine-induced contractions, an effect that was not changed by the transient receptor potential vanilloid type-1 blockers.CONCLUSIONS: Our data have suggested that CBD BDS reduces cholinergic-mediated contractility and that this effect is modulated by transient receptor potential vanilloid type-1 in rats but not in humans. CBD is the chemical ingredient of CBD BDS responsible for such activity. If confirmed in vivo, such results could provide a pharmacologic basis to explain, at least in part, the efficacy of Cannabis medicines in reducing incontinence episodes in patients with multiple sclerosis.

KW - Acetylcholine

KW - Animals

KW - Cannabidiol

KW - Cannabis

KW - Cholinergic Agonists

KW - Humans

KW - In Vitro Techniques

KW - Male

KW - Multiple Sclerosis

KW - Muscle Contraction

KW - Muscle, Smooth

KW - Plant Extracts

KW - Rats

KW - Rats, Wistar

KW - Urinary Bladder

KW - Urinary Incontinence

KW - Journal Article

U2 - 10.1016/j.urology.2010.12.006

DO - 10.1016/j.urology.2010.12.006

M3 - Article

VL - 77

SP - 1006.e9-1006.e15

JO - Urology

JF - Urology

SN - 0090-4295

IS - 4

ER -